Brought to you by 
Takeda pays up to $140mm for Envoy Therapeutics
03 Dec 2015
Executive Summary
Takeda Pharmaceutical Co. Ltd. and its Takeda America Holdings Inc. unit have agreed to pay up to $140mm to acquire privately held drug developer Envoy Therapeutics Inc. The deal value consists of an undisclosed up-front cash payment and progress-dependent earn-outs for preclinical projects. (Strategic Transactions will assume 25% of the $140mm is up front--$35mm--and the rest in earn-outs.)
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Includes Earnout
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda pays up to $140mm for Envoy Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice